May 18, 2015— AUA, New Orleans. A study of medical records of nearly 10,000 patients with prostate cancer shows that active surveillance (the updated form of watchful waiting) is suitable for most men with low-risk disease. Twelve to 15 years after diagnosis, these men are no more likely to die of prostate cancer than of other conditions and diseases. By contrast, the study shows, to avoid dying of prostate cancer men with high-risk disease may require aggressive "multimodal treatment" including surgery. ...continue reading "Active Surveillance For Low-Risk Prostate Cancer Does Not Shorten Life"

Active surveillance followed by selective treatment for men who have evidence of disease progression may be an option for some patients with early-stage prostate cancer.

Peter Carroll and a team at UCSF report the experience of a group of men men with prostate cancer who were managed with active surveillance.

...continue reading "Active Surveillance for Low-Risk Prostate Cancer Demands Careful Selection"

For men diagnosed with low-risk prostate cancer, active surveillance can be a sensible first step in managing the disease.

Mark Solloway and a team of urologists at University of Miami Miller School of Medicine have reported on outcomes for a group of their patients.

In all, 157 men with localized prostate cancer were followed on AS.

...continue reading "Most Low-Risk Prostate Cancer Patients Stay Treatment-Free for Five Years"

For patients with small, low-grade prostate cancer, delaying surgery -- even for years -- does not appear to increase the risk of the disease progressing to an incurable form.So finds a 10-year Johns Hopkins Medicine study. This discovery could prevent over-treatment, the authors say.

...continue reading "For Slow Growing Prostate Cancer Delay May be Reasonable, Hopkins Study Finds"